CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2020 Financial Results
-Dosing re-initiated in clinical trials of CTX001™ for patients with severe hemoglobinopathies-
- CTX001 has received orphan drug designation from the U.S. FDA for sickle cell disease (SCD)-
-Expands regenerative medicine portfolio through a collaboration with University Health Network (UHN), gaining access to hepatocytes-
ZUG, Switzerland and CAMBRIDGE, Mass., July 27, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today reported financial results for the second quarter ended June 30, 2020.
“We continue to make substantial progress driving our multiple, ongoing clinical development programs. Enrollment in our immuno-oncology trials is ongoing, and we’ve re-initiated dosing in our CTX001 trials,” said Samarth Kulkarni, Ph.D., Chief Executive Officer of CRISPR Therapeutics. “Further, we expect to report data from our CTX001 program targeting hemoglobinopathies and our CTX110 program later this year. Despite the challenges posed by COVID-19, we continue to execute on our programs and remain focused on our commitment to patients and their families.”
Recent Highlights and Outlook
Second Quarter 2020 Financial Results
CTX001 is being developed under a co-development and co-commercialization agreement between CRISPR Therapeutics and Vertex.
About CRISPR Therapeutics
CRISPR Forward-Looking Statement
CRISPR THERAPEUTICS® word mark and design logo, CTX001™, CTX110™, CTX120™, and CTX130™ are trademarks and registered trademarks of CRISPR Therapeutics AG. All other trademarks and registered trademarks are the property of their respective owners.
IoT Evolution #TECHSUPERSHOW Grand Opening Reception on Expo Floor